Volume 9 Supplement 2
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
© Martínez-Pérez et al; licensee BioMed Central Ltd. 2011
Published: 23 November 2011
To assess the effectiveness and functional capacity with rheumatoid artritis treated with biologic after dose reduction.
A retrospective study on a cohort of 13 patients diagnosed rheumatoid artritis treated with anti-TNF (10 patients with etanercept, and 3 with adalimumab) and clinical remission (DAS28 < 2.6) in the last 6 mounths, in which reducing the dosing. Clinical activity was evaluated by clinical activity index (DAS28), for functional capacity was used HAQ (Health Assessment Questionnaire). Others variables studied was visual analog scale (VAS). Analyzing before starting dose reduction, at 3 and 6 months.
p = 0,670
p = 0,001
p = 0,51
Of the 10 patients treated with etanercept 4 returned to their usual pattern, as well as 2 of the 3 patients with Adalimumab.
The reduction of etanercept and adalimumab doses in patients with rheumatoid arthritis in clinical remission (DAS28 <2.6) appears to be effective, since it manages to keep the DAS28 and the VAS. Not so the HAQ in which if there are significant differences that support that after the patient expresses reduce doses higher score on the test. Although the results 6 of 13 patients (46.2%) return to your regular schedule by mutual self-referred as subjectively feel worse and increase in seizures of exacerbation.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.